---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Specific populations questions"
description: "Specific populations questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding and Pediatric use. Questions: Is Trelegy safe during pregnancy? Can you breastfeed while using Trelegy? Is Trelegy approved for children? Is Trelegy safe for older adults? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Specific populations questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)  
Indication pages: [Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)

## Pregnancy and breastfeeding

<a id="trelegy-pregnancy"></a>

### Is Trelegy safe during pregnancy?

> “There are insufficient data on the use of TRELEGY ELLIPTA or its individual components, 
> fluticasone furoate, umeclidinium, and vilanterol, in pregnant women to inform a drug-associated 
> risk.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 17, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=17)

> “Labor or Delivery: TRELEGY ELLIPTA should be used during late gestation and labor only if 
> the potential benefit justifies the potential for risks related to beta-agonists interfering with 
> uterine contractility.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 17, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=17)

<a id="trelegy-breastfeeding"></a>

### Can you breastfeed while using Trelegy?

> “There is no information available on the presence of fluticasone furoate, umeclidinium, or 
> vilanterol in human milk; the effects on the breastfed child; or the effects on milk production. 
> Umeclidinium was detected in the plasma of offspring of lactating rats treated with 
> umeclidinium, suggesting its presence in maternal milk.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 18, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=18)

## Pediatric use

<a id="trelegy-pediatric-use"></a>

### Is Trelegy approved for children?

> “TRELEGY is not indicated for use in children and adolescents. The safety and efficacy in pediatric patients (aged 17 years and younger) have not been established.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=TRELEGY%20is%20not%20indicated%20for%20use%20in%20children,younger%29%20have%20not%20been%20established.)

## Specific populations

<a id="trelegy-older-adults"></a>

### Is Trelegy safe for older adults?

> “Based on available data, no adjustment of the dosage of TRELEGY ELLIPTA in geriatric 
> patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 19, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=19)

> “No overall differences in safety or 
> effectiveness were observed between these subjects and younger subjects, and other reported 
> clinical experience has not identified differences in responses between the elderly and younger 
> subjects.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=20)

Note: The second passage refers to the subjects aged 65 years and older in the label's COPD trials (Trials 1 to 3) and asthma trial (Trial 4).

<a id="trelegy-liver-impairment"></a>

### Can Trelegy be used with liver disease?

> “Use TRELEGY with caution in patients with moderate or severe hepatic impairment, as fluticasone furoate systemic exposure may increase by up to 3-fold. Monitor for corticosteroid-related side effects.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Use%20TRELEGY%20with%20caution%20in,Monitor%20for%20corticosteroid%2Drelated%20side%20effects.)

> “TRELEGY ELLIPTA has not been studied in subjects with hepatic impairment.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=20)

> “Patients with moderate hepatic impairment (Child-Pugh score of 7-9) showed no relevant 
> increases in Cmax or AUC, nor did protein binding differ between subjects with moderate hepatic 
> impairment and their healthy controls. Studies in subjects with severe hepatic impairment have 
> not been performed”

Source: [TRELEGY ELLIPTA: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=20)

Note: The third passage concerns umeclidinium.

<a id="trelegy-kidney-impairment"></a>

### Can Trelegy be used with kidney disease?

> “TRELEGY ELLIPTA has not been studied in subjects with renal impairment.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=20)

> “There were no significant increases in either fluticasone furoate or vilanterol exposure in subjects 
> with severe renal impairment (CrCl <30 mL/min) compared with healthy subjects. No dosage 
> adjustment is required in patients with renal impairment”

Source: [TRELEGY ELLIPTA: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=20)

> “Patients with severe renal impairment (CrCl <30 mL/min) showed no relevant increases in Cmax 
> or AUC, nor did protein binding differ between subjects with severe renal impairment and their 
> healthy controls.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=20)

Note: The third passage concerns umeclidinium.

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): All indications](https://www.evicenter.com/medical-information/trelegy-ellipta)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trelegy-ellipta/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/trelegy-ellipta/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/trelegy-ellipta/access-and-coverage)
